Frontiers in cellular and infection microbiology · 2026
Epidemiologic characteristics and clinical outcomes of respiratory syncytial virus in hospitalized care in Lebanon: a prospective observational study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khafaja Sarah, Merhi Sarah, Damaj Stephanie, Issaoui Saja, Boutros Celina F, Al-Kalamouni Habib, Soudani Nadia, Youssef Yolla, El-Zein Zeinab, Bou-Karroum Samer, Chmaisse Ahmad, Haj Magda, Houry Zeina, Chamseddine Sarah, Youssef Nour, Shaker Rouba, Naous Amal, Ghanem Soha, Lahoud Chantale, Shokr Imad, Feghali Rita, Breish David, Haddara Amani, Karam Maria, Zaraket Hassan, Dbaibo Ghassan S
Аннотация
INTRODUCTION: The aim of this study was to describe the epidemiology and clinical outcomes of respiratory syncytial virus (RSV) infection in hospitalized children and adults from a sentinel surveillance network in Lebanon, and to compare the RSV rates and seasonality before and during COVID-19 pandemic.
METHODS: This study was based on the data from the Lebanese component of the Global Influenza Hospital Surveillance Network (GIHSN) during three consecutive seasons between 2019-2021 at six hospitals, following a standardized protocol based on age-specific criteria. Specimens were tested for RSV. The epidemiologic, clinical, and severity characteristics were analyzed. Descriptive statistics were used to summarize demographics, RSV rate, and outcomes. Univariate analyses were performed using Pearson's Chi-square or Fisher's exact test, and associations were expressed as unadjusted odds ratios (95% CI). A p-value ≤0.05 was considered significant.
RESULTS: From January 2019 to September 2021, 2,626 of 7,081 eligible inpatients were enrolled in the study, with 188 tested positives for RSV (7.3%). The majority (74.5%) of RSV-positive subjects were children under 5 years of age, and 9.6% of patients were ≥ 65 years of age. The positivity rate varied across seasons (2.1%-11.1%) (p-value <0.001); the 2020-2021 season -was disrupted by COVID-19 pandemic - recording the lowest rate of 1.1% (p-value <0.001) during the typical winter months followed by an off-season RSV resurgence. Fever, cough, nasal congestion, wheezing, neurological symptoms, diarrhea and decreased oral intake were significantly associated with RSV infection (p < 0.05). Cough and wheezing were predominant in RSV-positive children <5 and adults aged ≥ 65 years. Among RSV-positive subjects, 8% required ICU admission, 5.3% received mechanical ventilation, and 2.7% died. Severe outcomes were more common in those ≥65 years, and the presence of ≥2 comorbidities and underlying cardiovascular disease significantly increased the risks of mechanical ventilation (OR = 7.44 [1.13-48.99], p-value 0.037 and OR = 8.32 [2.20-31.37], p-value 0.004, respectively) and in-hospital death (OR = 22.67 [1.91-268.50], p-value 0.013 and OR = 11.50 [1.82-72.85], p-value 0.016, respectively).
CONCLUSIONS: This study demonstrates the significant burden of RSV, especially in young infants with or without co-morbidities and in older adults with co-morbidities. Given the recent rollout of RSV vaccines and monoclonal antibodies, continued surveillance is needed to monitor changes in epidemiology, seasonality, and disease burden, especially in low- and middle-income countries.
METHODS: This study was based on the data from the Lebanese component of the Global Influenza Hospital Surveillance Network (GIHSN) during three consecutive seasons between 2019-2021 at six hospitals, following a standardized protocol based on age-specific criteria. Specimens were tested for RSV. The epidemiologic, clinical, and severity characteristics were analyzed. Descriptive statistics were used to summarize demographics, RSV rate, and outcomes. Univariate analyses were performed using Pearson's Chi-square or Fisher's exact test, and associations were expressed as unadjusted odds ratios (95% CI). A p-value ≤0.05 was considered significant.
RESULTS: From January 2019 to September 2021, 2,626 of 7,081 eligible inpatients were enrolled in the study, with 188 tested positives for RSV (7.3%). The majority (74.5%) of RSV-positive subjects were children under 5 years of age, and 9.6% of patients were ≥ 65 years of age. The positivity rate varied across seasons (2.1%-11.1%) (p-value <0.001); the 2020-2021 season -was disrupted by COVID-19 pandemic - recording the lowest rate of 1.1% (p-value <0.001) during the typical winter months followed by an off-season RSV resurgence. Fever, cough, nasal congestion, wheezing, neurological symptoms, diarrhea and decreased oral intake were significantly associated with RSV infection (p < 0.05). Cough and wheezing were predominant in RSV-positive children <5 and adults aged ≥ 65 years. Among RSV-positive subjects, 8% required ICU admission, 5.3% received mechanical ventilation, and 2.7% died. Severe outcomes were more common in those ≥65 years, and the presence of ≥2 comorbidities and underlying cardiovascular disease significantly increased the risks of mechanical ventilation (OR = 7.44 [1.13-48.99], p-value 0.037 and OR = 8.32 [2.20-31.37], p-value 0.004, respectively) and in-hospital death (OR = 22.67 [1.91-268.50], p-value 0.013 and OR = 11.50 [1.82-72.85], p-value 0.016, respectively).
CONCLUSIONS: This study demonstrates the significant burden of RSV, especially in young infants with or without co-morbidities and in older adults with co-morbidities. Given the recent rollout of RSV vaccines and monoclonal antibodies, continued surveillance is needed to monitor changes in epidemiology, seasonality, and disease burden, especially in low- and middle-income countries.